Previous 10 | Next 10 |
Tenax Therapeutics, Inc. (TENX) +70% after announcing acquisition of PH Precision Med.Aclaris Therapeutics (ACRS) +66% on positive data from mid-stage rheumatoid arthritis.Minerva Neurosciences (NERV) +42% on announcing sale of Seltorexant Royalty for up to $155M.China Natural ...
Program advances within the agreement’s initial two-year timeframe BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discoveri...
BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication mac...
BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces that management will present...
Cocrystal Pharma ([[COCP]] +1.4%) guides 2021 cash burn $800K/month, according to its presentation.As of 30 September, cash/equivalents stood at $31.8M, with no debt and preferred shares.The company expects cash runway beyond 2022.Source For further details see: Cocrystal sees 2021...
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces management will present at t...
SIFCO Industries (SIF) +54% on Q4 results.Creative Realities (CREX) +21%.Triterras (TRIT) +19%.AIM ImmunoTech (AIM) +17%.Bridgetown Holdings Limited (BTWN) +16%.Lightbridge Corporation (LTBR) +24% after nabbing patent in Eurasia for nuclear fuel assemblies.IZEA Worldwide (IZEA) +15%...
Cocrystal Pharma ([[COCP]] -9.2%) has selected CDI-45205 as the lead compound for further development against coronaviruses including SARS-CoV-2.CDI-45205 was one of the broad spectrum protease inhibitors that were obtained by an exclusive license from Kansas State University Research Fo...
CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2 BOTHELL, Wash., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company...
China HGS Real Estate (HGSH) +164%.Hexindai (HX) +32%.Sutro Biopharma (STRO) +25% as ovarian cancer drug study offers encouraging interim data.Domo (DOMO) +23% on Q3 results.CIIG Merger (CIIC) +22%.Sigma Labs (SGLB) +20%.Collective Growth Corporation (CGRO) +18%.Foresight Autonomous...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers wit...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...